Number of Studies:
Number of Patients:
Number of Sites:
Supporting Oncology research in Phases I-IV is one of our key pillar's in Pharm-Olam’s research foundation, and is considered a Center of Excellence due to the dedicated staff, technology, partnerships and investments being made by Pharm-Olam to support our Sponsors. From Regulatory to Project Management, and from Medical Monitoring to Data Management, our cross-functional, integrated solutions ensure compliance, data accuracy, and timely while improving cost efficiency through our Earned Value Management (EVM) model.
In addition, Pharm-Olam is often asked to perform rescue CRO services (augment or replace existing CRO service provider) for oncology clinical trials. Our ability to help clients achieve their original recruitment or enrollment goals frequently leads to Pharm-Olam being chosen for additional responsibilities, including Pharmacovigilance and Quality Assurance. Regardless of how we are engaged, Pharm-Olam is committed to your long-term success.
We have conducted CRO services across a broad range of oncology indications and treatment modalities, including:
Pharm-Olam offers sponsors and investigators the opportunity to discuss and formulate their research question about the design, conduct or analysis of data for their clinical trial.
Pharm-Olam offers full IND and Pre-IND support services for sponsors of all sizes and at all stages of their oncology research project.
Our Center of Excellence provides guidance and consulting, including:
This results in a reduced administrative burden on investigators because Pharm-Olam maintains, manages, and monitors INDs, including those involving external sites.
Pharm-Olam offers your oncology trial:
Pharm-Olam maintains staff dedicated to Oncology research through our Center of Excellence. We are highly experienced in managing the complexities of oncology study designs and adept at cohort and site management, coordination thereof.
About Pharm-Olam's dedicated Oncology team:
Childhood cancer is an increasingly important subset of oncology research. With less than 4% of all federal funding going to pediatric cancer research, sponsors are boldly furthering research on their own.
Pediatric trials often face a complex set of criteria and considerations, including informed consent, study endpoint definition, patient recruitment and access to patients over a designated amount of time.
Pharm-Olam’s pediatric specialty services are born of over two decades of progressive, complex research study experience. Our physicians and regulatory experts are able to provide advice specific for the conduct of studies in this unique and vulnerable population.